Variational AI is pleased to share that Rakovina Therapeutics (“Rakovina”) and Variational AI have expanded our collaboration to advance Rakovina’s kt-5000 series of ATR inhibitors, strengthening our joint commitment to accelerating oncology drug discovery through practical, design-first generative AI.
This expanded agreement builds on our existing work together and focuses on lead optimization of drug candidates generated by Variational AI’s Enki™ generative AI platform and selected by Rakovina for further evaluation in the kt-5000 ATR inhibitor program.
What’s new in the expanded collaboration
Under the expanded scope, Variational AI will apply Enki™ in an iterative optimization loop, generating and prioritizing multiple optimized compound designs to help Rakovina progress from early leads toward a clinical candidate faster, with the goal of achieving timelines measured in months rather than years.
As in our initial work together, Rakovina retains full control over which candidates to advance into laboratory testing and further development. Variational AI’s role is to support rapid design cycles that surface high-quality options; Rakovina determines which molecules move forward based on its strategy and experimental evaluation.
Importantly, this builds on the momentum already generated in the program. Rakovina has shared recent preclinical progress in the kt-5000 series, including results presented at the Society for NeuroOncology (SNO), highlighting efforts to advance CNS-penetrant ATR inhibitors. You can read a summary of those latest published results here: Update: Advancing CNS-Penetrant ATR Inhibitors with Enki.
What this means for our partners and the broader industry
This collaboration extension reflects a shared belief that the fastest path to high-quality candidates is not more screening, it’s better design cycles, supported by generative AI that can propose diverse, chemically realistic options while teams retain scientific and strategic control.
We’re excited to continue working with Rakovina as they advance the kt-5000 program and further explore the potential of ATR inhibition for patients who need better options.